Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond To Venetoclax In Combination With Chemotherapy

Andrew E. Place,Seth E. Karol,Christopher J. Forlenza,Marion Gambart,Todd M. Cooper,Christopher Fraser,Gunnar Cario,Maureen M O'Brien,Nicolas U. Gerber,Phillip Barnette,Dirk Reinhardt,Giridharan Ramsingh,Bo Tong,Kristina Unnebrink,Deeksha Vishwamitra,Fengjiao Dunbar,Betty A. Prine,Tammy L. Palenski,Mignon L. Loh

BLOOD（2020）

引用 8|浏览41

暂无评分

摘要

Introduction: Venetoclax (VEN) is an orally administered selective inhibitor of the B-cell lymphoma 2 (BCL2) antiapoptotic protein. VEN combined with chemotherapy (CTx) has demonstrated encouraging responses in a variety of hematologic malignancies. Here, we present safety, efficacy, and preliminary genomics results from our phase 1 study of VEN administered with CTx in pediatric patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要